Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

  1. Home
  2. Research Articles
Journal Title: 
Leukemia & Lymphoma
Primary Author: 
Sekeres MA
Author(s): 
Sekeres MA, Santini V, Díez-Campelo M, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel-Ferreiras D, Oliva EN, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan AM, Platzbecker U
Original Publication Date: 
Sunday, March 30, 2025
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/39535901/
Bone Marrow Disease(s):